OOIR: Observatory of International Research

Papers

(The H4-Index of Circulation is 125. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Heart Disease and Stroke Statistics—2021 Update	3365
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association	2625
COVID-19 and Cardiovascular Disease	1236
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association	1036
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association	918
Pulmonary Embolism in Patients With COVID-19	856
Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic	841
Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	819
Cardiovascular Disease in Chronic Kidney Disease	714
The Science Underlying COVID-19	618
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	614
Myocarditis With COVID-19 mRNA Vaccines	607
Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association	570
Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory From the American Heart Association	548
Obesity Is a Risk Factor for Severe COVID-19 Infection	543
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidel	517
Spectrum of Cardiac Manifestations in COVID-19	429
Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy	420
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome	412
Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association	407
The Variety of Cardiovascular Presentations of COVID-19	400
2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association	386
Part 1: Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	383
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines	359
Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association	351

Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction	350
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association	341
ST-Elevation Myocardial Infarction in Patients With COVID-19	332
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clini	323
Transcriptional and Cellular Diversity of the Human Heart	323
Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human	303
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease	301
Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China	296
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque	288
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association	275
Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation	266
Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association	255
Empagliflozin in Heart Failure	254
Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19	250
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association	246
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure	237
Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy	235
Cardiorespiratory Fitness in Youth: An Important Marker of Health: A Scientific Statement From the American Heart Association	233
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)	233
Evidence-Based Assessment of Genes in Dilated Cardiomyopathy	232
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk	229
Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19	226
Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis	225
Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	225
Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe	224
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction	219
Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children	215
Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?	215
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status	213
Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association	210
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association	210
Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device	209
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017	205
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial	198
Angiotensin Converting Enzyme 2	194
Extracellular Vesicle–Mediated Delivery of Circular RNA SCMH1 Promotes Functional Recovery in Rodent and Nonhuman Primate Ischemic Stroke Models	193
SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes	192
COVID-19, Arrhythmic Risk, and Inflammation	191
Severe COVID-19 Is a Microvascular Disease	191
Colchicine in Patients With Acute Coronary Syndrome	191
Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial	190
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction	188
Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung	188
Fruit and Vegetable Intake and Mortality	187
Microthrombi as a Major Cause of Cardiac Injury in COVID-19	185
Telemedicine Outpatient Cardiovascular Care During the COVID-19 Pandemic	182
Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association	182
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies	178
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction	175
Neonatal Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations	174

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes	172
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan	170
Part 5: Neonatal Resuscitation: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	169
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function	167
Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women	167
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population	166
Myocarditis Temporally Associated With COVID-19 Vaccination	166
Myocarditis After BNT162b2 and mRNA-1273 Vaccination	166
Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction	164
Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells	163
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Pr	161
Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells	156
Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis	153
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association	153
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease	153
Single-Cell Transcriptome Analysis Reveals Dynamic Cell Populations and Differential Gene Expression Patterns in Control and Aneurysmal Human Aortic Tissue	149
High-Resolution Transcriptomic Profiling of the Heart During Chronic Stress Reveals Cellular Drivers of Cardiac Fibrosis and Hypertrophy	147
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy	146
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?	146
Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association	145
Diagnosis and Management of Myocarditis in Children	143
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association	143
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure	143
Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity	141
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis	140
Deep Neural Networks Can Predict New-Onset Atrial Fibrillation From the 12-Lead ECG and Help Identify Those at Risk of Atrial Fibrillation–Related Stroke	140
High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19	139
Fate and State of Vascular Smooth Muscle Cells in Atherosclerosis	139
COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR)	138
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure	137
Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease	136
Cell-Free DNA to Detect Heart Allograft Acute Rejection	135
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis	134
Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction	134
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	133
Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy	133
Unexpected Features of Cardiac Pathology in COVID-19 Infection	132
Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guideline	132
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Gui	131
Blood Pressure Effects of Sodium Reduction	130
A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy	130
Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association	130
HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research	130
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease	129
Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial	128
Status of Cardiovascular Health in US Adults and Children Using the American Heart Association’s New “Life’s Essential 8” Metrics: Prevalence Estimates From the National Health and Nutrition Examinati	128
Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales	127
Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations	127
Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association	126
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase	126